MK-677, sold as ibutamoren, gets grouped with SARMs because it is sold in the same corner of the market, but it is a completely different kind of drug. It does not touch the androgen receptor, it does not build muscle by acting like testosterone, and — importantly — it does not suppress your natural testosterone. It is an orally active growth hormone secretagogue: a compound that makes your own pituitary release more growth hormone. That distinction changes almost everything about how to think about it, including the fact that it needs no PCT. This guide explains what it does, what the human data shows, and where its real downsides are.
How it works
MK-677 mimics ghrelin, the hormone that stimulates the ghrelin receptor (GHSR) in the brain. Activating that receptor prompts the pituitary to pulse out more growth hormone (GH), which in turn raises circulating IGF-1, the downstream mediator of most of GH's effects. Because it works through your own signalling machinery rather than by injecting GH, it produces a more physiological, pulsatile release. Being orally active and long-acting is its main practical selling point over injectable GH or peptide secretagogues.
What the human data shows
MK-677 actually has a reasonable amount of human study for this market, because it was investigated as a drug for years. The consistent findings:
- It reliably raises GH and IGF-1 in people, and the effect is sustained over months of daily dosing rather than fading quickly.
- In older adults, it has been shown to increase fat-free mass. A well-known year-long study in healthy older adults raised IGF-1 into the range of healthy young adults and increased fat-free mass.
- What it does not reliably deliver is a matching gain in strength or function. Raising a lean-mass number is not the same as making someone meaningfully stronger, and the trials did not show robust functional benefit.
So the honest read: MK-677 does what it says to the hormones — GH and IGF-1 go up, dependably — but translating that into the muscle and performance outcomes people actually want is far less certain. Much of the early weight gain is water and tissue, not necessarily contractile muscle.
Realistic effects
The most consistently reported effects, and the ones best supported, are:
- Increased appetite, often pronounced — a direct consequence of the ghrelin-mimicking mechanism. This is a feature for people trying to eat in a surplus and a nuisance for those trying to stay lean.
- Improved sleep depth in some users, plausibly linked to GH's relationship with slow-wave sleep, though this is variable.
- Noticeable water retention and a fuller, sometimes puffy look, especially early on.
- Skin, nail, and connective-tissue effects that people attribute to raised IGF-1.
Not suppressive — but not free of cost
The key point that separates MK-677 from RAD-140 and ligandrol: it is not an androgen, so it does not shut down the hypothalamic-pituitary-gonadal axis and there is no PCT rationale for it. You are not recovering testosterone production afterward because it was never suppressed. That is a genuine difference in kind, not degree.
That does not make it consequence-free. Its trade-offs are metabolic and fluid-related rather than hormonal-suppression-related:
- Water retention and edema are common, and some users report joint discomfort or carpal-tunnel-like symptoms, consistent with GH's known fluid effects.
- Insulin resistance is the most important concern. Sustained elevation of GH and IGF-1 can raise fasting glucose and reduce insulin sensitivity. Human studies of MK-677 have reported increases in fasting blood glucose and reduced insulin sensitivity, which is a real metabolic cost, particularly for anyone already at risk for glucose problems.
- Because appetite rises sharply, unwanted fat gain is easy if intake is not controlled.
Safety signals and open questions
Beyond the glucose and fluid effects, the honest caveats are about the long term and the population. The trials were mostly in older adults or specific patient groups, often not at the doses recreational users take, and chronic elevation of IGF-1 raises theoretical concerns that have not been resolved in this population. In one heart-failure trial, MK-677 was associated with worse outcomes, which is a reason not to wave away cardiovascular questions. As with the rest of the market, it is sold as an unregulated research chemical, so mislabelling and contamination are real, and what is in the bottle may not be MK-677 or may not be the stated dose.
Bottom line
MK-677 is not a SARM — it is a growth hormone secretagogue that raises GH and IGF-1 through your own pituitary, which is why it does not suppress testosterone and needs no PCT. The hormone effect is well documented; the payoff in real strength and function is much less certain, and a chunk of the early gain is water and appetite-driven mass. Its genuine costs are metabolic: water retention, big increases in hunger, and reduced insulin sensitivity with higher fasting glucose. Long-term safety at recreational doses is not established, and grey-market quality is unreliable. This is reference information, not medical advice.